Annual ROE
-80.27%
-46.56%-138.12%
31 December 2023
Summary:
XTL Biopharmaceuticals annual return on equity is currently -80.27%, with the most recent change of -46.56% (-138.12%) on 31 December 2023. During the last 3 years, it has risen by +1.51% (+1.85%). XTLB annual ROE is now -100.22% below its all-time high of 36.96 thousand%, reached on 31 December 2009.XTLB ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-14.91%
+52.85%+78.00%
31 March 2024
Summary:
XTL Biopharmaceuticals quarterly return on equity is currently -14.91%, with the most recent change of +52.85% (+78.00%) on 31 March 2024. Over the past year, it has increased by +58.14% (+79.59%). XTLB quarterly ROE is now -101.86% below its all-time high of 800.86%, reached on 30 June 2010.XTLB Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XTLB ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -138.1% | +79.6% |
| 3 y3 years | +1.9% | +80.5% |
| 5 y5 years | -260.8% | -194.6% |
XTLB ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -1083.7% | +1.9% | -148.6% | +81.0% |
| 5 y | 5 years | -260.8% | +1.9% | -148.6% | +81.0% |
| alltime | all time | -100.2% | +93.6% | -101.9% | +97.3% |
XTL Biopharmaceuticals ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | - | -14.91%(-78.0%) |
| Dec 2023 | -80.27%(+138.1%) | -67.76%(-7.2%) |
| Sept 2023 | - | -73.05%(-6.9%) |
| June 2023 | - | -78.45%(+23.0%) |
| Mar 2023 | - | -63.79%(+138.4%) |
| Dec 2022 | -33.71%(-513.1%) | -26.76%(-196.2%) |
| Sept 2022 | - | 27.83%(-9.3%) |
| June 2022 | - | 30.70%(+105.2%) |
| Mar 2022 | - | 14.96%(+37.8%) |
| Dec 2021 | 8.16%(-110.0%) | 10.86%(-114.2%) |
| Sept 2021 | - | -76.29%(+21.5%) |
| June 2021 | - | -62.77%(+29.6%) |
| Mar 2021 | - | -48.44%(+8.0%) |
| Dec 2020 | -81.78%(+598.4%) | -44.85%(+42.6%) |
| Sept 2020 | - | -31.46%(-12.7%) |
| June 2020 | - | -36.03%(-37.5%) |
| Mar 2020 | - | -57.65%(+583.1%) |
| Dec 2019 | -11.71%(-123.5%) | -8.44%(-153.6%) |
| Sept 2019 | - | 15.76%(-62.0%) |
| June 2019 | - | 41.47%(-48.4%) |
| Mar 2019 | - | 80.40%(+49.4%) |
| Dec 2018 | 49.91%(-331.3%) | 53.82%(+62.0%) |
| Sept 2018 | - | 33.22%(-34.5%) |
| June 2018 | - | 50.69%(+83.7%) |
| Mar 2018 | - | 27.59%(-213.3%) |
| Dec 2017 | -21.58%(-77.2%) | -24.35%(-63.5%) |
| Sept 2017 | - | -66.69%(-47.7%) |
| June 2017 | - | -127.43%(+52.4%) |
| Mar 2017 | - | -83.59%(+23.0%) |
| Dec 2016 | -94.72%(+7.4%) | -67.97%(-21.2%) |
| Sept 2016 | - | -86.28%(+14.9%) |
| June 2016 | - | -75.08%(+18.8%) |
| Mar 2016 | - | -63.20%(-10.7%) |
| Dec 2015 | -88.21%(+43.5%) | -70.74%(+39.9%) |
| Sept 2015 | - | -50.55%(-9.6%) |
| June 2015 | - | -55.90%(-12.4%) |
| Mar 2015 | - | -63.83%(+22.0%) |
| Dec 2014 | -61.48%(+3.7%) | -52.32%(-25.8%) |
| Sept 2014 | - | -70.55%(+45.3%) |
| June 2014 | - | -48.54%(-10.5%) |
| Mar 2014 | - | -54.25%(+22.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | -59.27%(+213.6%) | -44.19%(+130.8%) |
| Sept 2013 | - | -19.15%(-31.2%) |
| June 2013 | - | -27.85%(+14.0%) |
| Mar 2013 | - | -24.43%(+31.4%) |
| Dec 2012 | -18.90%(-46.1%) | -18.59%(-18.6%) |
| Sept 2012 | - | -22.84%(-27.7%) |
| June 2012 | - | -31.60%(+17.3%) |
| Mar 2012 | - | -26.94%(-10.3%) |
| Dec 2011 | -35.05%(-21.0%) | -30.03%(-7.7%) |
| Sept 2011 | - | -32.55%(-24.9%) |
| June 2011 | - | -43.34%(-40.7%) |
| Mar 2011 | - | -73.08%(-53.6%) |
| Dec 2010 | -44.35%(-100.1%) | -157.39%(-15.7%) |
| Sept 2010 | - | -186.65%(-123.3%) |
| June 2010 | - | 800.86%(+1133.4%) |
| Mar 2010 | - | 64.93%(-3.4%) |
| Dec 2009 | 36.96 K%(-3056.2%) | 67.20%(-163.0%) |
| Sept 2009 | - | -106.73%(-76.7%) |
| June 2009 | - | -458.96%(-16.1%) |
| Mar 2009 | - | -546.81%(+252.3%) |
| Dec 2008 | -1250.14%(+685.1%) | -155.23%(+4.9%) |
| Sept 2008 | - | -147.95%(+61.4%) |
| June 2008 | - | -91.67%(-52.7%) |
| Mar 2008 | - | -193.99%(+51.1%) |
| Dec 2007 | -159.23%(+79.0%) | -128.41%(-17.6%) |
| Sept 2007 | - | -155.79%(+21.8%) |
| June 2007 | - | -127.94%(+78.2%) |
| Mar 2007 | - | -71.78%(-6.6%) |
| Dec 2006 | -88.98%(-2.1%) | -76.88%(-0.1%) |
| Sept 2006 | - | -76.97%(-18.9%) |
| June 2006 | - | -94.88%(-17.5%) |
| Mar 2006 | - | -115.04%(+16.0%) |
| Dec 2005 | -90.85%(+10.9%) | -99.19%(+26.7%) |
| Sept 2005 | - | -78.30%(-10.4%) |
| June 2005 | - | -87.43%(-16.4%) |
| Mar 2005 | - | -104.57%(-9.4%) |
| Dec 2004 | -81.93%(+18.2%) | -115.46%(-8.5%) |
| Sept 2004 | - | -126.16%(+45.0%) |
| June 2004 | - | -87.01% |
| Dec 2003 | -69.33%(+40.9%) | - |
| Dec 2002 | -49.21%(+101.7%) | - |
| Dec 2001 | -24.40% | - |
FAQ
- What is XTL Biopharmaceuticals annual return on equity?
- What is the all time high annual ROE for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual ROE year-on-year change?
- What is XTL Biopharmaceuticals quarterly return on equity?
- What is the all time high quarterly ROE for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly ROE year-on-year change?
What is XTL Biopharmaceuticals annual return on equity?
The current annual ROE of XTLB is -80.27%
What is the all time high annual ROE for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual return on equity is 36.96 K%
What is XTL Biopharmaceuticals annual ROE year-on-year change?
Over the past year, XTLB annual return on equity has changed by -46.56% (-138.12%)
What is XTL Biopharmaceuticals quarterly return on equity?
The current quarterly ROE of XTLB is -14.91%
What is the all time high quarterly ROE for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly return on equity is 800.86%
What is XTL Biopharmaceuticals quarterly ROE year-on-year change?
Over the past year, XTLB quarterly return on equity has changed by +58.14% (+79.59%)